N. Hirayama
- Molecular Biology top 10%
- Computational Theory and Mathematics top 2%
- Pharmacology top 2%
- Organic Chemistry top 10%
- Pharmacology top 10%
- Co-authors
- Jun-Ichi GotoRyoichi KataokaMasato KoboriShinji SogaHiroki ShiraiYoshikatsu MurookaToshio MiyataIsao Fujii
- Topics
- Computational Drug Discovery Methods (13 papers)Cancer therapeutics and mechanisms (10 papers)Analytical Chemistry and Chromatography (9 papers)
- Journals
- Journal of the American Chemical SocietySHILAP Revista de lepidopterologíaBlood
- Partner nations
- JapanUnited StatesBelgium
In The Last Decade
N. Hirayama
75 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 109
- Molecular Biology 776
- Computational Theory and Mathematics 195
- Pharmacology 179
- Organic Chemistry 176
- Pharmacology 153
Countries citing papers authored by N. Hirayama
This map shows the geographic impact of N. Hirayama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Hirayama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Hirayama more than expected).
Fields of papers citing papers by N. Hirayama
This network shows the impact of papers produced by N. Hirayama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Hirayama. The network helps show where N. Hirayama may publish in the future.
Co-authorship network of co-authors of N. Hirayama
This figure shows the co-authorship network connecting the top 25 collaborators of N. Hirayama. A scholar is included among the top collaborators of N. Hirayama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Hirayama. N. Hirayama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 37 | |
| 2 | 31 | |
| 3 | 10 | |
| 4 | 27 | |
| 5 | 20 | |
| 6 | 126 | |
| 7 | 2 | |
| 8 | 7 | |
| 9 | 2 | |
| 10 | 13 | |
| 11 | 8 | |
| 12 | 36 | |
| 13 | 10 | |
| 14 | 40 | |
| 15 | 57 | |
| 16 | 8 | |
| 17 | 5 | |
| 18 | 4 | |
| 19 | 6 | |
| 20 | 76 STRUCTURE OF NEW ANTITUMOR ANTIBIOTICS, TETROCARCINS | 3 |
About N. Hirayama
N. Hirayama is a scholar working on Toxicology, Computational Theory and Mathematics and Organic Chemistry, having authored 81 papers that have together received 1.4k indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (13 papers), Cancer therapeutics and mechanisms (10 papers) and Analytical Chemistry and Chromatography (9 papers). The work is most often cited by research in Pharmacology (179 citations), Computational Theory and Mathematics (195 citations) and Molecular Biology (776 citations). N. Hirayama has collaborated with scholars based in Japan, United States and Belgium. Frequent co-authors include Jun-Ichi Goto, Ryoichi Kataoka, Masato Kobori, Shinji Soga, Hiroki Shirai, Yoshikatsu Murooka, Toshio Miyata, Isao Fujii, Yuko Izuhara and Charles van Ypersele de Strihou. Their work appears in journals such as Journal of the American Chemical Society, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.